Compare Elastic NV (ESTC) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Organon & Co. Common Stock — how do they compare? Elastic NV trades at $90.56 (market cap $9.90B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Elastic NV is far larger — about 2.7× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Elastic NV pays none. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 11 Days and Organon & Co. Common Stock for 0 Days on average.
| ESTC | OGN | |
|---|---|---|
Market Cap | $9.90B | $3.62B |
Volume | 1,629,456 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $99.91 | $13.81 |
52-Week Low | $43.30 | $5.70 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $9.04B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $94.32, down 1.26% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent product launches, including a metrics platform and serverless vector database, highlight innovation in AI and data search. Revenue grew to $1.48 billion in 2025, with a projected increase to $1.8 billion in 2026, though 2025 net income was negative.
The outlook is positive, driven by product innovation and earnings beats, but high valuation ratios and negative net income in 2025 pose risks. Analyst consensus is bullish with a $83.18 price target, suggesting potential upside. Key risks include execution challenges and competitive pressures in the software sector.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
